22
May
2024

SixPeaks Snags $110M from Versant, AZ for Drugs to Preserve Muscle and Shed Fat

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Versant, Novo-backed Antag Gets $84M for Weight Loss Drug with Combo Potential
Startup Snapshots: A Tetra-Binder for Obesity, and a ‘Mirror Peptide’ Engine
Santa Ana Bio Debuts with $168M to Develop Precision Inflammatory Medicines
Versant-Backed Nexo Gets $60M to Pursue Tough Cancer Targets